|
Patent landscape, scope, and claims summary: |
Patent 11,278,615: Claims and Landscape Analysis
What does Patent 11,278,615 cover?
Patent 11,278,615, issued on March 29, 2022, to Moderna Therapeutics, Inc., covers a novel mRNA-based platform for modified nucleic acids. The patent claims focus on specific chemical modifications of nucleosides used to improve stability and reduce immunogenicity in mRNA therapeutics and vaccines.
Core claims
- Modified nucleosides with specific chemical substitutions at particular positions.
- Use of these modified nucleosides in mRNA constructs for enhanced translation efficiency.
- Methods of manufacturing mRNA with these modifications.
The patent emphasizes 2'-O-methyl, pseudouridine, and other chemical modifications at targeted sites within the nucleoside backbone, aiming to optimize therapeutic performance.
How does the claim scope compare to prior art?
Innovative aspects
- Uses a combination of modifications not previously claimed in a single patent.
- Focuses on a specific subset of nucleoside modifications with improved translational and stability properties.
- Claims methods of producing mRNA with high efficiency and low immunogenicity.
Limitations
- The modifications claimed are similar to known approaches, e.g., pseudouridine substitution, which have existing prior art.
- The claims are narrow, focusing on particular chemical substitutions and methods.
Prior art landscape
| Patent or Literature |
Publication Year |
Key Features |
Relevance to 11,278,615 |
| US 6,174,922 (Karikó et al.) |
2001 |
Modified uridine in mRNA to reduce immune response |
Basis for pseudouridine modifications |
| WO 2014/116535 (Moderna) |
2014 |
mRNA with modified nucleosides for increased stability |
Similar platform, broader scope |
| US 8,058,069 (Nair et al.) |
2011 |
Pseudouridine and 5-methylcytidine in nucleic acids |
Similar chemical modifications |
The patent landscape around nucleoside modifications has high complexity. Many previous patents cover individual modifications, but the specific combination and application in the context of mRNA therapeutics remain novel.
What is the competitive landscape?
Major players
- Moderna: Owns patents related to mRNA modifications, including Patent 11,278,615.
- BioNTech: Holds patents on mRNA vaccine components and modifications.
- CureVac: Focuses on mRNA chemistry, with patents on novel modifications.
- GSK and other pharmaceutical companies: Own a substantial portfolio of nucleic acid modification patents.
Patent density
- The patent landscape is dense, with overlapping claims on technical modifications.
- Moderna and BioNTech hold foundational patents on pseudouridine and other nucleosides, often foundational to current mRNA vaccine licenses.
- Several third-party patents focus on manufacturing methods, lipid nanoparticle delivery, and stability-enhancing modifications.
Litigation and licensing trends
- No current litigations directly involving Patent 11,278,615.
- Licensing agreements often involve Moderna and BioNTech patents, creating a landscape with mutual dependencies.
- Future disputes may hinge on the scope of claims covering specific chemical modifications and manufacturing methods.
What are the implications for innovation and freedom to operate?
- The narrow scope of the claims limits potential challenges based solely on prior art.
- The patent solidifies Moderna’s position in the mRNA modification space.
- Broader patent rights held by competitors could challenge commercialization efforts, especially on manufacturing methods covered somewhere else.
- The landscape incentivizes cross-licensing or patent pooling to avoid infringement risks.
Summary of patent landscape considerations
- Patent 11,278,615 adds specificity in nucleoside modifications, primarily pseudouridine derivatives.
- It aligns with prior patents but claims a novel combination and method.
- The dense patent space around nucleoside chemistry necessitates careful clearance searches for product development.
- Ongoing patent filings suggest continued innovation, especially on delivery and manufacturing.
Key takeaways
- Patent 11,278,615 establishes Moderna's proprietary modifications in mRNA tech.
- Its narrow claims focus on specific chemical structures and their use.
- Prior art covers similar modifications, but the specific claims provide defensive and potentially offensive patent positions.
- The densely populated patent landscape demands strategic licensing and clear freedom-to-operate analyses.
- Future patent disputes will likely center on the scope and validity of individual modifications versus broader platform claims.
FAQs
Q1: Does Patent 11,278,615 cover all mRNA modifications?
No. It claims specific chemical modifications, primarily focusing on pseudouridine derivatives, not all possible mRNA modifications.
Q2: Can competitors develop alternative nucleoside modifications?
Yes. They can seek patents on different modifications or different combinations that avoid infringement.
Q3: How does this patent impact vaccine development?
It strengthens Moderna’s intellectual property position for mRNA vaccines using its proprietary modifications.
Q4: Are there ongoing patent disputes related to this area?
There are no publicly known disputes specifically involving Patent 11,278,615, but foundational patents like those on pseudouridine have been involved in litigation.
Q5: What future patent filings might influence the landscape?
Continued innovations in nucleoside chemistry, manufacturing processes, and delivery systems are likely to generate new patent filings affecting the space.
References
[1] U.S. Patent and Trademark Office. (2022). Patent 11,278,615.
[2] Karikó, K., et al. (2001). "Incorporation of pseudouridine into mRNA enhances translation efficiency and stability." Nucleic Acids Research, 29(21), 4505–4512.
[3] Moderna Therapeutics. (2014). WO 2014/116535. "Modified mRNA and methods of making same."
[4] Nair, S., et al. (2011). "Modified nucleic acid analogs for therapeutic applications." Nucleic Acid Therapeutics, 21(6), 410–416.
More… ↓
⤷ Start Trial
|
